A shocking state of affairs; the use of nanoparticles as simple carriers is dead and outdated. Stimuli-responsive nanoparticles have emerged as active participants in the therapeutic landscape, rather than inert molecule carriers. And this time they are here to join the ongoing war against an old enemy: bacteria.
No takes yet. Share an insight, caveat, or question.
Carina I. C. Crucho (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: